The Treasurer's Office said in a news release Thursday that 18 months of contract negotiations have resulted in “an untenable impasse" with CVS Caremark, "which potentially endangers the financial wel ...

The pharmacy giant manages the prescription drug benefit for the State Health Plan, but contract negotiations are at an impasse.

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

5. In a blow to Eli Lilly’s Zepbound, CVS Caremark chose Novo Nordisk’s Wegovy as the preferred GLP-1 weight loss medication for its largest commercial template formularies. A CVS spokesperson said ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.